International Journal of Gynecological Cancer最新文献

{"title":"Video-endoscopic inguinal sentinel lymph node biopsy with indocyanine green in vulvar cancer.","authors":"Filippo Maria Capomacchia, Nicolò Bizzarri, Aniello Foresta, Simona Fragomeni, Giorgia Garganese, Giovanni Scambia, Angelica Naldini","doi":"10.1136/ijgc-2024-005887","DOIUrl":"10.1136/ijgc-2024-005887","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101878"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring cervical cancer mortality in Brazil: an ecological study on socioeconomic and healthcare factors.","authors":"Agnaldo Lopes da Silva Filho, Guilherme Reis Romualdo, Matheus Eduardo Soares Pinhati, Gabriel Lage Neves, Juliana Almeida Oliveira, Renato Moretti-Marques, Angélica Nogueira-Rodrigues, Audrey Tieko Tsunoda, Eduardo Batista Cândido","doi":"10.1136/ijgc-2024-005738","DOIUrl":"10.1136/ijgc-2024-005738","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the correlation between socioeconomic and healthcare factors and cervical cancer mortality rates, as well as the accessibility to prevention and treatment across Brazilian states and macroregions. The aim is to highlight the multifaceted challenge of addressing cervical cancer mortality, particularly in low-and middle-income countries.</p><p><strong>Methods: </strong>This ecological study analyzed public data from the Brazilian National Institute of Cancer (INCA), the National Institute of Geography and Statistics (IBGE), and the Brazilian Ministry of Health. Data were collected on indicators such as the Human Development Index (HDI), physician density, average household income, human papillomavirus (HPV) vaccine coverage, Pap smear screening rates, radiotherapy machine density, and non-White population rates by state and macroregion across Brazil. Spearman's rank correlation test and simple linear regression analysis were employed.</p><p><strong>Results: </strong>Cervical cancer mortality rates are statistically lower in women with health insurance, positive self-perception of health, located in states with a higher HDI, higher per capita household income, greater density of physicians, and higher availability of radiotherapy machines. In contrast, mortality rates proportionally increase according to poverty levels, as expected, and rates of non-White population. Considering public health, HDI scores significantly affected Pap smear test coverage, the number of radiotherapy machines, and HPV vaccine uptake. The North and the Southeast regions have, respectively, the lowest and the highest socioeconomic indicators, proportional to their mortality rates. No significant correlation was found between mortality rates and HPV vaccine or Pap smear coverage.</p><p><strong>Conclusions: </strong>Cervical cancer mortality in Brazil is significantly influenced by socioeconomic and healthcare disparities. This study provides a data-driven basis for public health strategies that address both medical and social determinants of health.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101851"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of the annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer.","authors":"Luigi A De Vitis, Gabriella Schivardi, Aurora Gaeta, Giuseppe Caruso, Marina Rosanu, Lucia Ribero, Diletta Fumagalli, Jvan Casarin, Ilaria Betella, Giorgio Bogani, Carrie L Langstraat, Giovanni D Aletti, Nicoletta Colombo, Vanna Zanagnolo, Sara Gandini, Francesco Multinu","doi":"10.1016/j.ijgc.2025.101756","DOIUrl":"10.1016/j.ijgc.2025.101756","url":null,"abstract":"<p><strong>Objective: </strong>The annual recurrence risk model (ARRM), developed by the Surveillance in Cervical Cancer consortium and endorsed by the European Society of Gynecological Oncology, predicts the annual risk of cervical cancer recurrence. However, it lacks an external validation, which we aimed to address in the current retrospective study.</p><p><strong>Methods: </strong>We included patients with pathology confirmed T1a to T2b cervical cancers who underwent radical surgery at the European Institute of Oncology, Milan from January 2010 to December 2022. Using the ARRM risk calculator, patients were assigned a score from 0 to 100 points, which allowed classification into 5 risk groups (0, 1-25, 26-50, 51-75, and 76-100 points). Differences in 5-year disease-free survival were evaluated through log-rank tests with pairwise comparisons. Annual risk of recurrence was calculated using conditional survival analysis.</p><p><strong>Results: </strong>Overall, 411 patients with cervical cancers were included: 0 (0.0%) scored 0 points, 149 (36.3%) scored 1 to 25 points, 224 (54.5%) scored 26 to 50 points, 37 (9.0%) scored 51 to 75 points, and 1 (0.2%) scored 76 to 100 points. The patient from 76 to 100 points was excluded from further analyses. The 5-year disease-free survival rates were 96.3% (95% CI 90.0 to 98.6), 85.7% (95% CI 80.1% to 89.9%), and 66.6% (95% CI 47.3% to 80.2%) in groups 1 to 25, 26 to 50, and 51 to 75 points, respectively (p < .01). Compared with 26 to 50 and 51 to 75 points, the annual risk of recurrence was lower in the 1 to 25 points group, at around 1% from year 1 to 5.</p><p><strong>Conclusions: </strong>The ARRM tool confirmed its validity in stratifying cervical cancer into groups with significantly different disease-free survival rates in an independent large population from a tertiary center. The annual risk of recurrence should be carefully considered when tailoring follow-up, always taking into account the patient's perspective.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101756"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between magnetic resonance imaging-measured bone marrow cellularity and clinical outcomes among patients with cervical cancer treated with programmed cell death protein-1 inhibitors.","authors":"Jie Lou, Yi Li, Ruijie Li, Yusheng Guo, Bingxin Gong, Yanjie Yang, Yuan Zhang, Lian Yang","doi":"10.1016/j.ijgc.2025.101808","DOIUrl":"10.1016/j.ijgc.2025.101808","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to explore the prognostic value of bone marrow cellularity in the clinical outcomes of patients with cervical cancer treated with programmed cell death protein-1 (PD-1) inhibitors.</p><p><strong>Methods: </strong>This study retrospectively included patients with locally advanced or advanced cervical cancer receiving PD-1 inhibitor monotherapy or in combination with other therapies at Wuhan Union Hospital from May 2020 to December 2023. The mean signal intensity of the left posterior iliac bone, cerebrospinal fluid, and subcutaneous fat regions were measured on T1-weighted magnetic resonance images to calculate bone marrow cellularity. Optimal cut-off values for bone marrow cellularity and inflammatory indicators were determined using X-tile software. Progression-free survival and overall survival were analyzed using Cox regression and Kaplan-Meier analyses.</p><p><strong>Results: </strong>A total of 167 patients (88 with lower bone marrow cellularity and 79 with higher bone marrow cellularity) were included in this study. There were 124 squamous cell carcinoma, 30 adenocarcinoma, and 13 other pathologic types. Multivariate regression analysis showed that International Federation of Gynecology and Obstetrics stage III (progression-free survival: HR = 3.68, p < .001; overall survival: HR = 10.90, p < .001) and IV (progression-free survival: HR = 3.38, p = .002; overall survival: HR = 7.23, p = .003), other pathologic types (progression-free survival: HR = 2.86, p = .020; overall survival: HR = 3.84, p = .012), systemic immune-inflammation index ≥ 820.8 (progression-free survival: HR = 2.04, p = .029; overall survival: HR = 2.39, p = .045), and lower bone marrow cellularity (progression-free survival: HR = 1.74, p = .026; overall survival: HR = 2.35, p = .011) were significantly associated with poorer prognosis. Neutrophil-to-lymphocyte ratio ≥ 4.1 was an independent factor for overall survival (HR = 2.41, p = .049) but not for progression-free survival.</p><p><strong>Conclusions: </strong>Lower bone marrow cellularity is associated with poorer prognosis in patients with cervical cancer treated with PD-1 inhibitors.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 6","pages":"101808"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence on \"The prognostic impact of molecular classification in endometrial cancer that undergoes fertility-sparing treatment\" by De Vitis et al.","authors":"Filippo Alberto Ferrari, Francesco Raspagliesi, Giorgio Bogani","doi":"10.1016/j.ijgc.2025.101751","DOIUrl":"10.1016/j.ijgc.2025.101751","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101751"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143996668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of social media for academic and professional purposes by gynecologic oncologists.","authors":"Geetu Prakash Bhandoria, Aarthi S Jayraj, Shyamji Tiwari, Federico Migliorelli, Gregg Nelson, Gabriëlle H van Ramshorst, Joanna Kacperczyk-Bartnik, Martina Aida Angeles, Navya Nair, Houssein El Hajj, Nicolò Bizzarri","doi":"10.1136/ijgc-2024-005573","DOIUrl":"10.1136/ijgc-2024-005573","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the prevalence and patterns of social media use among gynecologic oncologists for professional and academic purposes.</p><p><strong>Methods: </strong>A prospective online survey between November and December 2022 targeted gynecologic oncology practitioners (gynecologic oncologists, surgical oncologists, medical oncologists, radiation/clinical oncologists, and onco-pathologists/pathologists). The survey, distributed via various social media platforms, included 40 questions to capture qualitative and quantitative data on social media use.</p><p><strong>Results: </strong>Of 131 respondents from 32 countries, 106 (80.9%) were gynecologic oncologists and affiliated with academic institutions (84.7%). Facebook (n=110, 83.9%), Twitter (n= 108, 82.4%), and Instagram (n=100, 76.3%) were the most used platforms. Respondents used social media to stay updated (n=101, 77.1%), network (n=97, 74%), learn about conferences and webinars (n=97, 74%), and engage in academic discussions (n=84, 64.1%). Following the COVID-19 pandemic, 100/129 (77.5%) reported increased social media use. However, only 32 (24.4%) used it to connect with patients, and concerns were raised about privacy and the need for separate professional and personal accounts. A quarter of respondents hesitated to share their opinions on social media due to the fear of controversy, with 26 (20%) experiencing cyberbullying, yet 120/130 (92.3%) believed it enabled junior professionals to express their views. Concerns about differentiating valid content, information reliability, and the professional perception of sourcing knowledge from social media were noted. Gender, age, specialty, and income level influenced patterns of social media use, with variations in preferences for platforms, content engagement, and purposes, highlighting a complex landscape of social media interaction among gynecologic oncologists.</p><p><strong>Conclusion: </strong>While the use of social media among gynecologic oncologists is prevalent, particularly for academic and professional development, challenges such as cyberbullying, privacy concerns, and the need for formal training in social media navigation persist. Tailored training programs and guidelines could enhance social media's effective and ethical use in this field, promoting a safe environment for professional expression and engagement.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101845"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carbon dye versus indocyanine green for sentinel lymph node mapping in endometrial cancer: a prospective dual-center study.","authors":"Yagmur Minareci, Hamdullah Sozen, Aysel Bayram, Buket Altinkara Hacioglu, Huseyin Oguz Yuvanc, Ramazan Murdan, Mustafa Albayrak, Atahan Toyran, Cennet Yildiz, Mehmet Guven Gunver, Semen Onder, Samet Topuz, Mehmet Yavuz Salihoglu","doi":"10.1016/j.ijgc.2025.101749","DOIUrl":"10.1016/j.ijgc.2025.101749","url":null,"abstract":"<p><strong>Objective: </strong>To compare the detection rates and diagnostic accuracy of sentinel lymph node (SLN) mapping using carbon dye and indocyanine green (ICG) in patients with early-stage endometrial cancer.</p><p><strong>Methods: </strong>The present study was a dual-center, prospective cohort study conducted between September 2021 and August 2022 involving patients with early-stage endometrial cancer. For SLN mapping, one center exclusively used carbon dye, while the other solely used ICG. Subsequently, all patients underwent complete systematic pelvic lymphadenectomy. The detection rates, sensitivity, and negative predictive value of SLN mapping were analyzed.</p><p><strong>Results: </strong>This study included 179 patients, of whom 89 (49.7%) were mapped using carbon dye and 90 (50.3%) were mapped using ICG laparoscopically. Unilateral detection rates of SLNs were similar, 94.4% (84/89) for carbon dye and 97.8% (88/90) for ICG (p = .25). In contrast, bilateral detection rates were significantly higher with carbon dye compared to ICG (82.0% [73/89] vs 64.4% [58/90], p = 0.008). The sensitivity and negative predictive value were both 100% for ICG and 83.3% and 98.8% for carbon dye, respectively. The empty node packet rate was 5.6% (5/90) for ICG and 0% (0/89) for carbon dye (p = .17). Although this difference did not reach statistical significance, all cases of empty node packets were observed in patients with successful unilateral but failed bilateral detection.</p><p><strong>Conclusions: </strong>Carbon dye is a safe and effective agent for SLN mapping, demonstrating adequate detection rates, satisfactory sensitivity, and a high negative predictive value in patients with early-stage endometrial cancer. The use of carbon dye might reduce the rate of empty node packets, thereby enhancing the accuracy of nodal evaluation. While carbon dye may be a promising alternative tracer, particularly in low-resource settings, further comparative studies are needed to evaluate its cost-effectiveness relative to other widely used tracers, including blue dyes.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101749"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant chemotherapy in stage IB2 to IB3 cervical cancer: because we can or because we must?","authors":"Philippe Morice, Sebastien Gouy, Marie Plante, Nadeem Abu-Rustum","doi":"10.1016/j.ijgc.2025.101770","DOIUrl":"10.1016/j.ijgc.2025.101770","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101770"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of chemotherapy on survival in patients aged ≥65 years with locoregionally cervical cancer who undergo radiotherapy: a Surveillance, Epidemiology, and End Results database analysis.","authors":"JunFang Liao, Tie Xu, JiaoMei Zhou, NanJie Xiao, Man Zhao, TianShu Zhao, Miao Peng, ZhiJian Chen","doi":"10.1016/j.ijgc.2025.101747","DOIUrl":"10.1016/j.ijgc.2025.101747","url":null,"abstract":"<p><strong>Objective: </strong>Cervical cancer remains a global health challenge, particularly among patients aged ≥65 years, who often face poorer outcomes. This study aims to evaluate the clinical significance of chemotherapy in older patients (≥65 years) who undergo definitive radiotherapy for cervical cancer, using data from the Surveillance, Epidemiology, and End Results database.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted using data from the Surveillance, Epidemiology, and End Results 18 Registries, focusing on patients with cervical cancer aged ≥65 years who were diagnosed between 2004 and 2017. Patients receiving surgery or those without radiotherapy were excluded. Propensity score matching was used to balance the baseline characteristics in patients treated with and those without chemotherapy. Overall survival and cancer-specific survival were analyzed using Kaplan-Meier curves, log-rank tests, and Cox proportional hazards models.</p><p><strong>Results: </strong>A total of 2958 patients met the inclusion criteria, and 69.8% (n = 2067) received chemotherapy. Chemotherapy significantly improved 5- and 10-year overall survival rates (47.8% vs 26.9%, 28.5% vs 11.1%, respectively; HR 0.55, 95% CI 0.49 to 0.61, p < .0001) and cancer-specific survival rates (58.7% vs 43.8%, 48.3% vs 38.7%, HR 0.64, 95% CI 0.56 to 0.73). Multi-variate analysis identified chemotherapy, International Federation of Gynecology and Obstetrics stage, and histology as independent prognostic factors for both overall survival and cancer-specific survival. The impact of chemotherapy decreased slightly in more advanced stages, particularly stage IVA, but remained beneficial in earlier stages and among the oldest age groups (≥85 years).</p><p><strong>Conclusions: </strong>Chemotherapy significantly improves both overall survival and cancer-specific survival in patients aged ≥65 years with locoregionally advanced cervical cancer who undergo radiotherapy. These findings strongly support the inclusion of chemotherapy in treatment regimens for older patients, regardless of age, to optimize survival outcomes and ensure comprehensive care. Further research is essential to develop better strategies for managing advanced-stage diseases in older patients.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101747"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of adjuvant radiation therapy and impact on the survival of patients with lymph node-positive squamous cell carcinoma of the vulva.","authors":"Lakeisha Mulugeta-Gordon, Stefan Gysler, Nawar A Latif, Emily M Ko, Robert L Giuntoli, Sarah H Kim, Dimitrios Nasioudis","doi":"10.1016/j.ijgc.2025.101748","DOIUrl":"10.1016/j.ijgc.2025.101748","url":null,"abstract":"<p><strong>Objective: </strong>Patients with squamous cell carcinoma of the vulva with inguinal lymph node metastases undergo adjuvant treatment to reduce the risk of recurrence. We examined the patterns of adjuvant treatment delivery and their impact on overall survival.</p><p><strong>Methods: </strong>Patients diagnosed between January 2004 and December 2015 with apparent early-stage squamous cell carcinoma of the vulva, who underwent surgical resection with lymph node sampling/dissection, had at least 1 positive lymph node, and received adjuvant radiation therapy were identified. A total of 3 quality metrics associated with improved survival were evaluated: utilization of radiosensitizing chemotherapy, receipt of radiation therapy within 8 weeks of surgery, and completion of radiation therapy within 8 weeks of initiation. Overall survival was examined after the generation of Kaplan-Meier curves and compared using the log-rank test. A Cox model was constructed to control for the a priori confounding factors.</p><p><strong>Results: </strong>A total of 1181 patients were identified, with a median number of positive lymph nodes of 2 (range; 1-14). All 3 quality metrics were met by 238 patients (20.2%). These patients were younger (median age, 59 vs 67 years, p<.001), more likely to have private insurance (52.1% vs 33.4%, p<.001), and less likely to have medical co-morbidities (22.7% vs 30.5%; p=.017). Patients who received adjuvant radiotherapy meeting all quality metrics had better overall survival than those who did not (p<.001); the 5-year overall survival rates were 62.6% and 42.8%, respectively. After controlling for patient age, race, insurance status, presence of medical co-morbidities, tumor size, performance of comprehensive lymphadenectomy, and number of positive lymph nodes, adjuvant radiation therapy meeting all quality metrics was associated with better overall survival (HR 0.56, 95% CI 0.44 to 0.72).</p><p><strong>Conclusions: </strong>Approximately 1 in 5 patients with lymph node-positive vulvar cancer received adjuvant treatment that met all quality metrics associated with improved survival.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101748"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}